Blood analysis good at predicting how tumours will respond; Proteomic test useful when doctors have no tumour tissue
LONDON, April 30 (Reuters) – Testing for specific cancer protein markers in lung cancer patients’ blood helps find those more likely to respond to Tarceva, a drug sold by Roche (ROG.VX) and OSI Pharmaceuticals OSIP.O, data showed on Friday.